Selection for international MATWIN board
Digital meeting
13-14 October, 2020
MATWIN (Maturation & Accelerating Translation within Industry) is an innovation platform that aims to accelerate transfer of oncology innovation from academia & SMEs to clinical development. 13 Pharma partners and numerous academic opinion leaders review proposals for partnership opportunities that offer most promise for patient well being. ENYO Pharma project is selected for a pitch to participating VC investors for start-up funds.
EASL – The Digital International Liver Congress 2020
August 27-29, 2020
Digital congress
ENYO Pharma was connected from the 27th to the 29th of August at the digital EASL International Liver Congress and present 2 posters.
“Characterization of EYP001 a novel, potent and selective FXR agonist in in vitro 3D human liver models”
“A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis”
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium – 18 August 2020 – CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners.
New release of neXtProt with ENYO Pharma human interactome data
ENYO Pharma and the CALIPHO group at SIB Swiss Institute of Bioinformatics are pleased to announce the neXtProt data release 2020-07-17, that integrates the human protein interactome curated by the company as “GOLD” data. This dataset includes 108,000 descriptions of protein interactions from 324 papers with the capture of the experimental method (PSI-MI). When the sequence used in the protein-protein interaction experiment is known, this information has been collected and is available in neXtProt as interaction mapping annotations.
ENYO Pharma selected in the FrenchTech 120
ENYO Pharma is proud to be part of the FrenchTech 120 with such promising companies. It is a strong recognition from the French State.
Latest Press Release 